Last reviewed · How we verify
Adriamycin
At a glance
| Generic name | Adriamycin |
|---|---|
| Also known as | ADR, Doxorubicin, Doxorubicin Hydrochloride, Adriamycin PFS, Adrimaycin RDF |
| Sponsor | Johann Wolfgang Goethe University Hospital |
| Target | Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Acute lymphoid leukemia
- Acute myeloid leukemia, disease
- Advanced ovarian cancer
- Burkitt's lymphoma
- Carcinoma of breast
- Carcinoma of female breast
- Diffuse non-Hodgkin's lymphoma, large cell
- Follicular non-Hodgkin's lymphoma
- Hodgkin's disease
- Invasive Bladder Malignancy
- Kaposi's sarcoma
- Kaposi's sarcoma associated with AIDS
- Malignant tumor of lung
- Malignant tumor of ovary
- Malignant tumor of thyroid gland
- Metastatic Breast Carcinoma
- Metastatic Gastric Cancer
- Multiple myeloma
- Nephroblastoma
- Neuroblastoma
Common side effects
- Alopecia
- Vomiting
- Leukopenia Grade 3
- Nausea
- Systemic infection
- Shock, sepsis
- Cardiac dysfunction - Asymptomatic
- Leukopenia Grade 4
- Cardiac dysfunction - Transient
- Cardiac dysfunction - Symptomatic
- Thrombocytopenia Grade 4
Serious adverse events
- Cardiomyopathy
- Arrhythmias
- Secondary Malignancies
- Extravasation and Tissue Necrosis
- Severe Myelosuppression
- Tumor Lysis Syndrome
- Anaphylaxis
- Cardiogenic shock
- Necrotizing colitis
- Gastrointestinal tract bleeding
Key clinical trials
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (PHASE3)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (PHASE2, PHASE3)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adriamycin CI brief — competitive landscape report
- Adriamycin updates RSS · CI watch RSS
- Johann Wolfgang Goethe University Hospital portfolio CI